AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.890
+0.160 (5.86%)
At close: Nov 4, 2024, 4:00 PM
2.660
-0.230 (-7.96%)
Pre-market: Nov 5, 2024, 6:26 AM EST
AbCellera Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 32.96 | 38.03 | 485.42 | 375.2 | 233.16 | 11.61 | Upgrade
|
| Revenue Growth (YoY) | -34.59% | -92.17% | 29.38% | 60.92% | 1907.88% | 31.49% | Upgrade
|
| Cost of Revenue | 175.66 | 175.66 | 174.32 | 107.58 | 56.54 | 10.11 | Upgrade
|
| Gross Profit | -142.7 | -137.63 | 311.11 | 267.63 | 176.62 | 1.5 | Upgrade
|
| Selling, General & Admin | 85.4 | 75.18 | 66.76 | 48.76 | 15.75 | 4.01 | Upgrade
|
| Operating Expenses | 165.37 | 99.57 | 86.2 | 63.21 | 20.59 | 5.62 | Upgrade
|
| Operating Income | -308.06 | -237.21 | 224.91 | 204.41 | 156.03 | -4.12 | Upgrade
|
| Interest Expense | - | - | - | - | -6.81 | -0.21 | Upgrade
|
| Interest & Investment Income | 40.77 | 42.25 | 16.08 | 3.33 | 0.29 | 0.16 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | - | 0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | 59.09 | 14.9 | 9.65 | 11.91 | 8.32 | 1.77 | Upgrade
|
| EBT Excluding Unusual Items | -208.2 | -180.06 | 250.64 | 219.65 | 157.83 | -2.21 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2.1 | 2.1 | -1.7 | -0.5 | - | - | Upgrade
|
| Asset Writedown | - | - | -8.4 | - | - | - | Upgrade
|
| Other Unusual Items | 3.93 | 3.93 | -1.45 | - | - | - | Upgrade
|
| Pretax Income | -202.17 | -174.03 | 239.1 | 219.15 | 157.83 | -2.21 | Upgrade
|
| Income Tax Expense | -26.37 | -27.63 | 80.58 | 65.69 | 38.92 | - | Upgrade
|
| Net Income | -175.8 | -146.4 | 158.52 | 153.46 | 118.92 | -2.21 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 33.82 | - | Upgrade
|
| Net Income to Common | -175.8 | -146.4 | 158.52 | 153.46 | 85.1 | -2.21 | Upgrade
|
| Net Income Growth | - | - | 3.29% | 29.05% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 293 | 289 | 285 | 276 | 159 | 151 | Upgrade
|
| Shares Outstanding (Diluted) | 293 | 289 | 315 | 318 | 263 | 151 | Upgrade
|
| Shares Change (YoY) | 1.70% | -8.15% | -1.09% | 20.96% | 73.88% | -11.68% | Upgrade
|
| EPS (Basic) | -0.60 | -0.51 | 0.56 | 0.56 | 0.53 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.61 | -0.51 | 0.50 | 0.48 | 0.45 | -0.01 | Upgrade
|
| EPS Growth | - | - | 4.17% | 6.21% | - | - | Upgrade
|
| Free Cash Flow | -197.36 | -120.82 | 206.7 | 186.13 | 13.02 | -1.3 | Upgrade
|
| Free Cash Flow Per Share | -0.67 | -0.42 | 0.66 | 0.58 | 0.05 | -0.01 | Upgrade
|
| Gross Margin | - | - | 64.09% | 71.33% | 75.75% | 12.91% | Upgrade
|
| Operating Margin | -934.60% | -623.82% | 46.33% | 54.48% | 66.92% | -35.45% | Upgrade
|
| Profit Margin | -533.33% | -385.00% | 32.66% | 40.90% | 36.50% | -19.04% | Upgrade
|
| Free Cash Flow Margin | -598.76% | -317.75% | 42.58% | 49.61% | 5.58% | -11.22% | Upgrade
|
| EBITDA | -222.24 | -212.81 | 244.35 | 218.88 | 160.87 | -2.51 | Upgrade
|
| EBITDA Margin | - | - | 50.34% | 58.34% | 69.00% | -21.64% | Upgrade
|
| D&A For EBITDA | 85.82 | 24.4 | 19.44 | 14.47 | 4.84 | 1.6 | Upgrade
|
| EBIT | -308.06 | -237.21 | 224.91 | 204.41 | 156.03 | -4.12 | Upgrade
|
| EBIT Margin | - | - | 46.33% | 54.48% | 66.92% | -35.45% | Upgrade
|
| Effective Tax Rate | - | - | 33.70% | 29.97% | 24.66% | - | Upgrade
|
| Revenue as Reported | 32.96 | 38.03 | 485.42 | 375.2 | 233.16 | 11.61 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.